1026.0000 18.70 (1.86%)
NSE Jun 11, 2025 15:31 PM
Volume: 87,699
 

1026.00
1.86%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.
More from Alivus Life Sciences Ltd.
Recommended